Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Dose Escalation Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumor

NCT04805060 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT04805060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04805060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Dose Escalation Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumor
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 23, 2021
Completion date
December 12, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

terminal malignant tumors